Maximize your investments! Explore the top 3 dividend stocks poised for explosive growth in 2024. Unlock wealth and transform your portfolio now.
Top 3 Dividend Stocks in 2024
As we step into the New Year, investors are on the lookout for dividend stocks that offer both stability and growth potential. The S&P 500 closed 2023 with an impressive 20% gain, making it crucial for investors to choose wisely. We’ve identified three dividend stocks that not only have durable competitive advantages but also exhibit growth potential. These stocks are expected to provide an annual return of at least 10% over the next five years.
Brady Corp (BRC)
Business Overview: Founded in 1914, Brady Corp (NYSE: BRC) specializes in manufacturing and marketing specialty materials, including absorbents, labels, pipes and valves, signs, tags, tapes, and printers. With annual revenue exceeding $1.3 billion, Brady has a strong presence in the market.
Financial Performance: In the first quarter of fiscal year 2024, ending October 31, 2023, Brady Corp reported a 2.9% growth in revenue to $332 million. Although slightly below expectations, adjusted earnings per share (EPS) of $1 surpassed estimates, indicating a positive trend. Organic revenue grew by 1.5%, driven by improvements in the Americas and Asia region.
Financial Outlook: Brady Corp has consistently demonstrated strong earnings growth, with EPS growing at a rate of more than 10% annually over the past decade. The company maintains a leadership position in its product categories, ensuring a durable competitive advantage. With a dividend yield of 1.6% and a price-to-earnings (P/E) ratio of 14.7, below the fair value estimate of 19, Brady Corp appears undervalued. The potential total returns could reach 11.6% per year over the next five years.
Polaris (PII)
Business Overview: Polaris (NYSE: PII) is a global powersports manufacturer that designs, engineers, and manufactures snowmobiles, all-terrain vehicles (ATVs), and motorcycles. Operating under 30-plus brands, including Polaris, Ranger, RZR, Sportsman, Indian Motorcycle, Slingshot, and Transamerican Auto Parts, the company generated $8.6 billion in sales in 2022.
Financial Performance: In its recent Q3 results, Polaris reported a 3.8% decrease in revenue to $2.25 billion. However, the off-road segment, the company’s largest component, saw a 6% improvement. Polaris updated its guidance for 2023, expecting a 3% to 5% increase in revenue for the year.
Long-Term Growth: Polaris has a solid outlook for long-term growth, driven by the ongoing replacement need for ATVs and snowmobiles, international market expansion, bolt-on acquisitions, and margin expansion. With a competitive advantage through brand names, low-cost production, and a strong industry presence, Polaris is well-positioned for the future.
Dividend and Valuation: Polaris offers a dividend yield of 2.7% and has increased its dividend for 28 consecutive years. With a P/E ratio of 9.7, compared to a fair value P/E of 15, the stock is considered undervalued. The estimated total returns for Polaris are projected to be 15.3% per year over the next five years.
Bristol-Myers Squibb (BMY)
Business Overview: Bristol-Myers Squibb (NYSE: BMY) is a prominent drug maker specializing in cardiovascular and anti-cancer therapeutics, with annual revenues surpassing $40 billion. The company’s top-selling products include Revlimid, Opdivo, and Eliquis.
Financial Performance: In the 2023 third quarter, Bristol-Myers Squibb reported a 2.2% decline in revenue to $10.97 billion, in line with estimates. Adjusted EPS of $2 slightly grew from the prior year, exceeding expectations. Key products like Eliquis, Opdivo, and Orencia contributed to the overall performance.
Profitability and Dividends: Bristol-Myers Squibb is highly profitable, with adjusted EPS expected to be in the range of $7.50 to $7.65 for 2023. The company’s dividend yield is an impressive 4.7%, reflecting its ability to generate sufficient cash flow to reward shareholders.
Valuation and Expected Returns: With a P/E of 7 compared to the fair value P/E of 11, BMY stock is considered undervalued. The combination of expected EPS growth, a substantial dividend, and a potential rise in the P/E multiple suggests an expected annual return of over 16% for Bristol-Myers Squibb over the next five years.
Conclusion:
Investors seeking reliable dividend stocks for 2024 and beyond should consider companies with strong competitive advantages, consistent growth potential, and solid dividend coverage. Brady Corp, Polaris, and Bristol-Myers Squibb stand out as promising options, offering a mix of stability, growth, and dividends that align with investors’ long-term goals. As always, it’s essential for investors to conduct thorough research and consider their risk tolerance before making investment decisions.
Also Read- Leaked iPhone 16 Pro and iPhone 16 Pro Max Features You Can’t Afford to Miss!
3 thoughts on “Investor’s Goldmine: The 2024 3 Dividend Stocks That Could Double Your Money”